{
    "id": 30607,
    "fullName": "MET Y1003F",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MET Y1003F lies within the juxtamembrane domain of the Met protein (PMID: 16397241). Y1003F results in reduced Cbl binding and ubiquitination of Met, Mapk pathway activation, and increased cell proliferation in culture (PMID: 16397241, PMID: 31279006).",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                },
                {
                    "id": 1974,
                    "pubMedId": 16397241,
                    "title": "Somatic mutations lead to an oncogenic deletion of met in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16397241"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4233,
        "geneSymbol": "MET",
        "terms": [
            "MET",
            "AUTS9",
            "c-Met",
            "DFNB97",
            "HGFR",
            "RCCP2"
        ]
    },
    "variant": "Y1003F",
    "createDate": "07/30/2019",
    "updateDate": "08/16/2019",
    "referenceTranscriptCoordinates": {
        "id": 181579,
        "transcript": "NM_000245",
        "gDna": "chr7:g.116771969A>T",
        "cDna": "c.3008A>T",
        "protein": "p.Y1003F",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18393,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) inhibited growth of transformed cells expressing MET Y1003F in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 32832,
                "profileName": "MET Y1003F"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18394,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tepotinib (MSC2156119J) inhibited growth of transformed cells expressing MET Y1003F in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 32832,
                "profileName": "MET Y1003F"
            },
            "therapy": {
                "id": 1398,
                "therapyName": "Tepotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18392,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing MET Y1003F in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 32832,
                "profileName": "MET Y1003F"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18397,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells expressing MET Y1003F in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 32832,
                "profileName": "MET Y1003F"
            },
            "therapy": {
                "id": 1030,
                "therapyName": "Merestinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18395,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Savolitinib (AZD6094) inhibited growth of transformed cells expressing MET Y1003F in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 32832,
                "profileName": "MET Y1003F"
            },
            "therapy": {
                "id": 2161,
                "therapyName": "Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18399,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing MET Y1003F were resistant to Tivantinib (ARQ197) in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 32832,
                "profileName": "MET Y1003F"
            },
            "therapy": {
                "id": 636,
                "therapyName": "Tivantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18396,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing MET Y1003F in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 32832,
                "profileName": "MET Y1003F"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18398,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glesatinib (MGCD265) inhibited growth of transformed cells expressing MET Y1003F in culture (PMID: 31279006).",
            "molecularProfile": {
                "id": 32832,
                "profileName": "MET Y1003F"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16006,
                    "pubMedId": 31279006,
                    "title": "Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In\u00a0Vitro.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31279006"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32832,
            "profileName": "MET Y1003F",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 181579,
            "transcript": "NM_000245",
            "gDna": "chr7:g.116771969A>T",
            "cDna": "c.3008A>T",
            "protein": "p.Y1003F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}